Illumina Inc. (ILMN) Stock
NASDAQILMN has an Alpha Score of 43 out of 100 (weak), computed on Oct 26, 2026 from 3 of 4 sub-scores. 10 members of Congress disclosed 42 trades in ILMN since 2018: 22 purchases and 20 sales, most recently Gilbert Cisneros (purchase, Feb 10, 2026). 9 of the hedge funds AlphaScala tracks reported ILMN in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is ARK Invest's at $183.74M. Company insiders reported 0 open-market buys and 68 sales on SEC Form 4 in the 90 days to Oct 30, 2026. Its trailing P/E ratio is 53.0 and its net margin 18.4% (key statistics as of Oct 29, 2026).
What is ILMN's Alpha Score?
How it works →Alpha Score of 43 reflects weak overall profile with strong momentum, poor value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 26, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Illumina Inc. (ILMN)?
Most recent: Gilbert Cisneros (purchase, Feb 10, 2026); records start Oct 24, 2018.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-02-10 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-31 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-30 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-30 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-06-09 | purchase | $1k – $15k |
| Tom Kean Jr. R-NJ · House | 2025-04-01 | purchase | $1k – $15k |
| Michael Burgess R-TX · House | 2024-09-03 | sale | $15k – $50k |
| Michael Burgess R-TX · House | 2024-08-30 | sale | $15k – $50k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all ILMN political trades →Which hedge funds own ILMN?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| ARK Invest Cathie Wood | 1.05M | $183.74M | -7% |
| Renaissance Technologies Jim Simons (founder) | 827K | $145.35M | -15% |
| Marshall Wace | 102K | $17.98M | -80% |
| Millennium Management Israel Englander | 85K | $14.90M | -59% |
| D.E. Shaw David Shaw | 49K | $8.68M | +4% |
| Point72 Steve Cohen | 39K | $6.86M | -27% |
| Hussman Investment Trust John Hussman | 13K | $2.22M | NEW |
| Bridgewater Associates Ray Dalio | 13K | $2.21M | -1% |
| Blackstone | 9K | $1.53M | -62% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Illumina Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 4, 26 | Meister Keith A. | Director | SELL | 7.5K | $1.6M |
| Sep 4, 26 | Meister Keith A. | Director | SELL | 100.7K | $22.0M |
| Sep 4, 26 | Meister Keith A. | Director | SELL | 11.4K | $2.5M |
| Sep 3, 26 | Meister Keith A. | Director | SELL | 8.4K | $1.8M |
| Sep 3, 26 | Meister Keith A. | Director | SELL | 13.3K | $2.9M |
| Sep 3, 26 | Meister Keith A. | Director | SELL | 14.2K | $3.1M |
| Sep 3, 26 | Meister Keith A. | Director | SELL | 9.7K | $2.1M |
| Sep 3, 26 | Meister Keith A. | Director | SELL | 13.7K | $3.0M |
| Sep 3, 26 | Meister Keith A. | Director | SELL | 6.7K | $1.5M |
| Sep 3, 26 | Meister Keith A. | Director | SELL | 10.0K | $2.2M |
SEC Form 4 filings as of Oct 30, 2026
See cluster-buy signals across all tickers →What are ILMN's key statistics?
Key statistics as of Oct 29, 2026
How does ILMN's valuation compare with the Healthcare sector?
| Metric | ILMN | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 53.0 | 27.1 | 97 |
| Net margin | 18.36% | 5.48% | 139 |
| Return on equity | 31.08% | 6.84% | 158 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 2, 2026). P/E excludes loss-making companies.
ILMN price chart
Powered by TradingViewWhat does Illumina Inc. do?
Illumina, Inc. develops, manufactures, and markets sequencing- and array-based solutions for genetic and genomic analysis worldwide, including in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company provides instruments and consumables such as reagents, flow cells, and library preparation kits, along with whole-genome sequencing kits for genomes of varying size and complexity, and targeted resequencing kits for exomes, specific genes, RNA, and other genomic regions. Its offerings support whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services, serving research, clinical, and applied markets through the Core Illumina segment. These technologies enable large-scale analysis of genetic variation and function, powering advancements in life science research, translational and consumer genomics, and molecular diagnostics. Founded in 1998 and headquartered in San Diego, California, Illumina, Inc. delivers innovative, flexible, and scalable platforms to meet diverse customer needs in genomic solutions.